WO2002036826A3 - Del-1 and benign prostatic hyperplasia - Google Patents

Del-1 and benign prostatic hyperplasia Download PDF

Info

Publication number
WO2002036826A3
WO2002036826A3 PCT/US2001/042915 US0142915W WO0236826A3 WO 2002036826 A3 WO2002036826 A3 WO 2002036826A3 US 0142915 W US0142915 W US 0142915W WO 0236826 A3 WO0236826 A3 WO 0236826A3
Authority
WO
WIPO (PCT)
Prior art keywords
del
benign prostatic
prostatic hyperplasia
bph
changes
Prior art date
Application number
PCT/US2001/042915
Other languages
French (fr)
Other versions
WO2002036826A2 (en
Inventor
William E Munger
Prakash Kulkarni
Robert H Getzenberg
Original Assignee
Gene Logic Inc
Japan Tobacco Inc
William E Munger
Prakash Kulkarni
Robert H Getzenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Japan Tobacco Inc, William E Munger, Prakash Kulkarni, Robert H Getzenberg filed Critical Gene Logic Inc
Priority to AU2002232403A priority Critical patent/AU2002232403A1/en
Publication of WO2002036826A2 publication Critical patent/WO2002036826A2/en
Publication of WO2002036826A3 publication Critical patent/WO2002036826A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention relates generally to the changes in gene expression in Benign Prostatic Hyperplasis (BPH). The invention relates specifically to the human gene Del-1 which is differentially expressed in BPH compared to normal prostate tissue.
PCT/US2001/042915 2000-11-06 2001-11-05 Del-1 and benign prostatic hyperplasia WO2002036826A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002232403A AU2002232403A1 (en) 2000-11-06 2001-11-05 Del-1 and benign prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24567400P 2000-11-06 2000-11-06
US60/245,674 2000-11-06

Publications (2)

Publication Number Publication Date
WO2002036826A2 WO2002036826A2 (en) 2002-05-10
WO2002036826A3 true WO2002036826A3 (en) 2003-11-20

Family

ID=22927616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042915 WO2002036826A2 (en) 2000-11-06 2001-11-05 Del-1 and benign prostatic hyperplasia

Country Status (2)

Country Link
AU (1) AU2002232403A1 (en)
WO (1) WO2002036826A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4817233B2 (en) 2003-06-30 2011-11-16 学校法人日本大学 Extracellular matrix deposited protein
JP5791022B2 (en) 2010-12-13 2015-10-07 学校法人日本大学 Cell migration regulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877281A (en) * 1995-06-07 1999-03-02 Progenitor, Inc. Developmentally-regulated endothelial cell locus-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877281A (en) * 1995-06-07 1999-03-02 Progenitor, Inc. Developmentally-regulated endothelial cell locus-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAKEHI YOSHIYUKI ET AL: "Molecular differentiation of histologic and symptomatic BPH.", JOURNAL OF UROLOGY, vol. 165, no. 5 Supplement, May 2001 (2001-05-01), Annual Meeting of the American Urological Association, Inc.;Anaheim, California, USA; June 02-07, 2001, pages 207, XP009003596, ISSN: 0022-5347 *
PARTIN A W ET AL: "NUCLEAR MATRIX PROTEIN PATTERNS IN HUMAN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, no. 4, 15 February 1993 (1993-02-15), pages 744 - 746, XP000673445, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2002036826A2 (en) 2002-05-10
AU2002232403A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
IL141235A0 (en) Combined use of an alpha-adrenoceptor antagonist and amuscarinic antagonist in the treatment of benign prostatic hyperplasi
AU2002236507A1 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
PT1242671E (en) Enzymes useful for changing the properties of polyester
AU4136401A (en) Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
WO1999014346A3 (en) SENSE mRNA THERAPY
AU4559200A (en) Use of phyllanthus for treating chronically inflammatory and fibrotic processes
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
WO2002036826A3 (en) Del-1 and benign prostatic hyperplasia
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
WO2005042741A3 (en) Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
WO2001098456A3 (en) IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
WO2002046362A3 (en) Gene associated with benign prostatic hyperplasia in humans
WO2002048173A3 (en) Expression of a cadherin-like protein in benign prostatic hyperplasia
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
WO2002077162A3 (en) Gene (t23490) associated with benign prostatic hyperplasia
NO994903D0 (en) Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
WO2001021217A3 (en) Method of treating cells of the prostate prophylactically or therapeutically
AU2001275264A1 (en) Treatment of fibrous substrates with silsesquioxanes and stainblockers
AU2002226085A1 (en) Active-site engineering of nucleotidyltransferases and enzymatic methods for the synthesis of natural and "unnatural" udp- and nucleotide sugars
HUP9904408A2 (en) Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
AU2002317553A1 (en) Genes associated with benign prostatic hyperplasia
AU2001283152A1 (en) Identification of cdnas associated with benign prostatic hyperplasia
WO2002002754A3 (en) Regulation of human alpha-hydroxysteroid dehydrogenase-like enzyme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP